OGR for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
General provisions related to the pharmaceutical industry including prescription drug affordability and access, intellectual property, privacy, 340B drug discount program policy, and clinical trial diversity issues; FY2024 Appropriations Process; Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169); Monitoring public health emergency designation; Issues related to the role of pharmacy benefit managers in drug pricing.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Medicare/Medicaid MMM
Issues related to Medicare Part D access and drug pricing negotiation, compulsory licensing policy, and insulin policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Trade (domestic/foreign) TRD
Issues related to WTO TRIPS. Intellectual property issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.